Live feed08:05:00·168dNEWSReleasevia QuantisnowAptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid TumorsByQuantisnow·Wall Street's wire, on your screen.APVO· Aptevo Therapeutics Inc.Health Care
